CAR-T Cell Therapy (Chimeric Antigen Receptor T-Cell)
CAR-T Cell Therapy is a living drug gene therapy where patient T-cells are harvested, genetically modified in a specialized laboratory to express synthetic CD19 chimeric antigen receptors (NexCAR19 / Kymriah), and re-infused to eradicate refractory blood cancers.
CAR-T cell therapy
Clinical Overview & Disease Information
CAR-T Cell Therapy is a living drug gene therapy where patient T-cells are harvested, genetically modified in a specialized laboratory to express synthetic CD19 chimeric antigen receptors (NexCAR19 / Kymriah), and re-infused to eradicate refractory blood cancers.
Signs & Symptoms
- • Low blood counts prior to lymphodepletion
- • Fatigue and night sweats
- • Cytokine Release Syndrome (CRS): High fever, tachycardia, hypotension
- • Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS): Confusion, speech difficulty
- • Transient B-cell aplasia
- • Grade 3/4 Cytokine Release Syndrome (High fever, severe hypoxia, shock)
- • Severe ICANS seizures or obtundation
Causes & Risk Factors
Primary Causes & Etiology
- Relapsed / Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
- Relapsed Multiple Myeloma (BCMA target)
Who is at Higher Risk?
- Patients failing 2 or more prior lines of chemotherapy or stem cell transplant
Diagnostic Evaluation & Testing
| Diagnostic Test | Clinical Purpose / What It Shows |
|---|---|
| Flow Cytometry CD19 / CD20 Expression & Bone Marrow Aspiration | Confirms presence of target CD19 surface antigens on malignant lymphoblasts |
| Serum Ferritin, CRP & IL-6 Inflammatory Biomarkers | Monitors early onset of Cytokine Release Syndrome (CRS) |
Comprehensive Treatment Options
Autologous Engineered CAR-T Cell Re-Infusion
Intravenous infusion of genetically modified CD19-targeting CAR T-cells following 3-day conditioning lymphodepletion.
Bridging Chemotherapy & Lymphodepleting Conditioning (Fludarabine + Cyclophosphamide)
Pre-infusion chemotherapy protocol to clear host T-cells, creating optimal microenvironment for CAR-T expansion.
Advanced Medical Technologies Available in Partner Hospitals
Possible Complications If Untreated
Recovery Timeline, Diet & Lifestyle Care
Recovery Timeline
| Procedure / Stage | Expected Recovery Duration |
|---|---|
| Leukapheresis T-Cell Harvest | Day -28 |
| Lymphodepleting Chemotherapy | Days -5 to -3 |
| CAR-T Cell Infusion (Day 0) | 1 hour infusion |
| Inpatient BMT Unit Monitoring | 14 to 21 days |
| Outpatient Remission Surveillance | 3 to 6 months |
Recommended Post-Treatment Diet
- Strict neutropenic clean diet
- Boiled water
- High calorie protein shakes
Essential Lifestyle Changes
- Stay within 30 mins of BMT center for 4 weeks
- Daily handwriting test (ICANS monitoring)
- Strict hand hygiene
Prevention & Long-Term Health
Frequently Asked Questions
Is CAR-T cell therapy a single one-time treatment?
Yes! Unlike multi-cycle chemotherapy, CAR-T is administered as a single one-time intravenous infusion of living immune cells.
What is NexCAR19?
NexCAR19 is India's first indigenously developed humanized CD19 CAR-T cell therapy offering world-class efficacy at 1/10th the global cost.
Top Recommended Specialists Available
Dr. Gaurav Dixit
Head – Haematology Oncology & Bone Marrow Transplant (Unit II)
View Doctor Profile →
Dr. Aditya Gupta
Chairperson - Neurosurgery & CNS Radiosurgery & Co-Chief - Cyberknife Centre
View Doctor Profile →
Dr. Rupinder Sekhon
Chief - Gynae Oncology & Sr. Consultant: Surgical Oncology
View Doctor Profile →
Dr. Tapan Singh Chauhan
Sr. Consultant - Surgical Oncology, Robotics, GI & HPB, Gynae & Peritoneal Surface Oncology
View Doctor Profile →
Dr. Namita Jaggi
Chairperson - Lab Services & Infection Control; Chief - Education & Research
View Doctor Profile →
Dr. Parveen Yadav
Chief & Senior Consultant - Minimal Invasive & Robotic Thoracic Onco Surgery
View Doctor Profile →
Dr. Subodh Chandra Pande
Chief - Radiation Oncology & Co-Chief - Cyberknife Centre
View Doctor Profile →
Dr. Arun Singh Danewa
Senior Consultant – Pediatric-Haemato-Oncology & Bone Marrow Transplant (Unit II)
View Doctor Profile →Global Cost Comparison Matrix
| Procedure | USA (Avg) | India (ISG) | Turkey (Avg) | Thailand (Avg) |
|---|---|---|---|---|
| CAR-T cell therapy | $450,000 | $42,000 | $120,000 | $140,000 |
Request Free Clinical Opinion & Cost Estimate
Upload your diagnostic reports or medical summary for a free review by leading specialists within 24-48 hours.
Get Free Treatment EstimateCommonly Prescribed Medications
- Tocilizumab 8mg/kg IV (CRS management)
- Dexamethasone 10mg IV
- Fludarabine 30mg/m2 + Cyclophosphamide 500mg/m2
- IVIG Immunoglobulin
International Patient Guide
- Passport & Medical Visa
- Bone Marrow Biopsy & Flow Cytometry CD
- Full Medical Record